Public Company Global News & Press Release Distribution

Public Company News

All
APAC

Uxin to Report First Quarter Fiscal Year 2025 Financial Results on September 23, 2024

BEIJING, Sept. 18, 2024 /PRNewswire/ -- Uxin Limited ("Uxin" or the "Company") (Nasdaq: UXIN),China's leading used car retailer, today announced that it will release its unaudited financial results for the first quarter of fiscal year 2025 endedJune 30, 2024, before the U.S. market opens on Septe...

2024-09-18 17:00 4623

Maitong Sunshine Cultural Begins Trading on the OTC Markets

NEW YORK, Sept. 18, 2024 /PRNewswire/ -- Maitong Sunshine Cultural Development Co., Limited (OTC Markets: MGSD, the "Company") today announced that the Company begins trading on the OTC Markets. The Company is a professional enterprise that provides cultural and tourism services with distinctive ...

2024-09-18 16:30 4360

Senhwa Biosciences Announces IND Submission to US FDA for Pilot Study of Pidnarulex Pharmacodynamics in Patients with Advanced Solid Tumors sponsored by NCI

TAIPEI and SAN DIEGO, Sept. 17, 2024 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), , a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced that an Investigational New Drug (IND) application for Pidnarulex ...

2024-09-18 10:06 3078

Breakthrough in Long COVID: An investigator-initiated trial (IIT) with Hyundai Bioscience's Xafty by UCSD

SAN DIEGO, Sept. 17, 2024 /PRNewswire/ -- Hyundai Bioscience USA announced that it has signed an MOU with theUniversity of California San Diego (UCSD) to conduct an investigator-initiated trial to evaluate the efficacy of Xafty®, a niclosamide-based antiviral developed by its Korean headquarters,...

2024-09-18 09:26 3840

XCharge, Asia Green Fund's Portfolio, Successfully Listed on Nasdaq

BEIJING, Sept. 14, 2024 /PRNewswire/ -- XCHG Limited (XCHARGE) (NASDAQ: XCH) announced the pricing of its initial public offering. XCharge, founded in 2015, is a global leader in integrated EV charging solutions, focusing on Innovative New Energy Technologies and Sustainable Development . The Co...

2024-09-18 09:22 3153

Mega Matrix Announces That the Short Drama "Revenge Beyond the Grave", Will Be Released on September 18 at FlexTV

PALO ALTO, Calif., Sept. 17, 2024 /PRNewswire/ -- Mega Matrix Corp. ("MPU" or the "Company") (NYSE American: MPU), today announced that it will launch its revenge short drama "Revenge Beyond the Grave" onSeptember 18th at FlexTV. This is no ordinary tale of vengeance, as it delves deeper into t...

2024-09-18 00:49 3042

Mega Matrix Announces That the Short Drama

Datasea's New 5G AI Multimodal Agreements Have Already Generated $9.0 Million of 5G-AI Services

Agreements Boost Fiscal 2025 Revenue and Expand Datasea's 5G Application Market Positioning inChina BEIJING, Sept. 17, 2024 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), aNevada-based company focused on innovative high-tech acoustics and 5G-Artificial Intelligence ("A...

2024-09-17 21:45 2716

Subgroup Analysis from Pivotal WU-KONG1B Study Exhibits Robust Efficacy of Sunvozertinib in Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations Across Different Baseline Characteristics

Results of subgroup analysis from the pivotal WU-KONG1B study in relapsed or refractory NSCLC with EGFR exon20ins presented at ESMO 2024 * Sunvozertinib demonstrated promising anti-tumor efficacy, regardless of EGFR exon20ins region classification, race, region, baseline brain metastasis, prio...

2024-09-17 15:47 3022

Harvard Business School examines DBS' AI strategy and implementation in its first case study focusing on AI in an Asian bank

Authored by Feng Zhu, HBS Professor of Business Administration, the case highlights the bank's use of AI and takeaways for companies navigating technological change SINGAPORE, Sept. 16, 2024 /PRNewswire/ -- Harvard Business School (HBS) has published a case study on DBS' strategy towards Artific...

2024-09-16 22:00 4502

Intelligent Living Application Group Inc. Regains Compliance with Nasdaq's Minimum Bid Price Rule

HONG KONG, Sept. 16, 2024 /PRNewswire/ -- Intelligent Living Application Group Inc. (NASDAQ:ILAG ) ("Intelligent Living"...

2024-09-16 21:00 5789

Concord Medical Announces Obtaining Large Medical Equipment Procurement License for Its Proton Therapy Equipment

BEIJING, Sept. 16, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention inChina, today announced that Guangzhou Concord Cancer Center ("Guangzhou H...

2024-09-16 20:00 3287

Game-Changing Lidar OT128 from Hesai Unveiled at IAA Transportation, Accelerating Autonomous Vehicles' Commercial Deployment

HANNOVER, Germany, Sept. 16, 2024 /PRNewswire/ -- Hesai Technology (Nasdaq: HSAI), the global leader in lidar technology, is launching its powerful new lidar solution OT128 atEurope's biggest commercial vehicle trade fair IAA Transportation inHannover (booth location: Hall 12, #C71). Hesai's OT12...

2024-09-16 20:00 2434

Vazyme Leads Life Science Innovation, Boosting Research Breakthroughs in mIDH1 Cancer Treatment

NANJING, China, Sept. 16, 2024 /PRNewswire/ -- Vazyme (688105.SH), a leading life science technology company, significantly contributed to groundbreaking research published in Science Magazine through its innovative products. The study, which focuses on how mutant IDH1 inhibition activates tumor ...

2024-09-16 19:00 2919

Vazyme Leads Life Science Innovation, Boosting Research Breakthroughs in mIDH1 Cancer Treatment

Antennova Releases Latest Data of CD73 Inhibitor ATN-037, including a DCR of 89.5%, in a Mini Oral at ESMO Congress 2024

* In patients with non-small cell lung cancer (NSCLC) or melanoma who had acquired resistance to checkpoint inhibitors (CPIs), ATN-037 in combination with KEYTRUDA®(pembrolizumab) demonstrated an overall response rate (ORR) of 21.1% and a disease control rate (DCR) of 89.5%. * Data from the...

2024-09-16 18:00 3206

China Automotive Systems Announces Annual Meeting on September 24, 2024

CAAS announces the conference call and webcast information for the Annual Meeting of Stockholders to be held onTuesday, September 24, 2024 at 9:00 AM local time, or 9:00 PM EDT onMonday, September 23, 2024 WUHAN, China, Sept. 16, 2024 /PRNewswire/ -- China Automotive Systems, Inc. (Nasdaq: CAAS)...

2024-09-16 18:00 5534

Akeso's Ivonescimab plus Chemo in First-Line Triple-negative Breast Cancer Showed Promising Preliminary Efficacy and Good Safety at ESMO 2024

HONG KONG, Sept. 16, 2024 /PRNewswire/ -- At the 2024 European Society for Medical Oncology (ESMO) Conference, Akeso (9926.HK) published the phase 2 results from its ivonescimab in combination with chemotherapy as a first-line (1L) treatment for triple-negative breast cancer (TNBC). The prelimina...

2024-09-16 15:35 5827

Risen Energy Champions Environmental Stewardship for a Greener Future

NINGBO, China, Sept. 15, 2024 /PRNewswire/ -- On September 20, World Cleanup Day 2024 kicks off during the Clean Up the World Weekend (CUW Weekend), themed "make room for life." Since joining the UN Global Compact (UNGC) in 2021, Risen Energy, a leader in global photovoltaic (PV) innovation, has ...

2024-09-16 10:00 3197

Akeso Published Ivonescimab plus Ligufalimab as First-Line Treatment for PD-L1-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at ESMO 2024

Head-to-Head Phase 3 Trial Compared to Pembrolizumab Initiated HONG KONG, Sept. 15, 2024 /PRNewswire/ -- At the 2024 European Society for Medical Oncology (ESMO) Conference, Akeso released the Phase 2 clinical results of its internally developed PD-1/VEGF bispecific antibody, ivonescimab, with or...

2024-09-15 15:10 4211

Breakthrough Therapy designation for Sanbexin sublingual tablets granted by the United States Food and Drug Administration

NANJING, China, Sept. 14, 2024 /PRNewswire/ -- On September 2, 2024, Simcere Pharmaceuticals Group Ltd. (2096.HK) announced that Sanbexin Sublingual Tablets (Edaravone and Dexborneol sublingual tablets), an innovative drug for stroke, has been granted the Breakthrough Therapy designation by the U...

2024-09-14 19:43 5031

Breakthrough Therapy designation for Sanbexin sublingual tablets granted by the United States Food and Drug Administration

Harbour BioMed Announces the Latest Clinical Data on the First-in-Class Fully Human Anti-B7H7/HHLA2 Monoclonal Antibody HBM1020 at the ESMO Congress 2024

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Sept. 14, 2024 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immuno...

2024-09-14 16:06 4938

1 ... 256 257 258259260 261 262 ... 763

Week's Top Stories

Tetra Pak Introduces Industry-first Carton Packaging for Shelf-stable Tuna to Support Southeast Asia's Growing Tuna Industry

[Picked up by 287 media titles]

2026-07-13 10:00

Tetra Pak Introduces Industry-first Carton Packaging for Shelf-stable Tuna to Support Southeast Asia's Growing Tuna Industry

Klook signs an expanded two-year partnership with Korea Tourism Organization

[Picked up by 286 media titles]

2026-07-16 17:49